Lv6
2080 积分 2023-03-30 加入
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
6小时前
已完结
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
6小时前
已完结
Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations
6小时前
已完结
乳腺癌单病种分级诊疗专家共识（2025版）
12小时前
已完结
PD-1/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: Synergistic mechanisms and research progress
6天前
已完结
Angiogenesis and immune microenvironment in triple-negative breast cancer: Targeted therapy
6天前
已完结
Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence
7天前
已完结
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
7天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
8天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
8天前
已完结
皖公网安备34019202002308
